帕博利珠单抗联合贝伐珠单抗治疗初治黑色素瘤脑转移的Ⅱ期试验
这项两中心Ⅱ期试验纳入37例未接受抗PD-(L)-1治疗、伴至少一个无症状非出血性5-20 mm黑色素瘤脑转移且无需立即局部治疗或类固醇的患者,给予贝伐珠单抗联合帕博利珠单抗治疗。脑转移缓解率(主要终点)为54.1%(95%CI 36.9-70.5),颅外缓解率为56.3%(95%CI 37.7-73.6),中位颅内无进展生存期为2.2年(95%CI 0.41-未达到),中位总生存期为4.3年(95%CI 1.6-未达到),4年总生存率为51.6%。结论认为该方案耐受性良好且在初治黑色素瘤脑转移患者中显示出可观活性及令人鼓舞的总生存,值得进一步评估。
要点
- 脑转移缓解率(主要终点)为54.1%(95%CI 36.9-70.5)。
- 中位颅内无进展生存期2.2年(95%CI 0.41-未达到),中位总生存期4.3年(95%CI 1.6-未达到)。
- 贝伐珠单抗和帕博利珠单抗的3级治疗相关不良事件率分别为10.8%和18.9%。
核心结论
- 帕博利珠单抗联合贝伐珠单抗耐受性良好,在初治黑色素瘤脑转移患者中显示出可观活性及令人鼓舞的总生存,值得进一步评估该方案。
研究设计与样本
- 两中心Ⅱ期试验,纳入37例未接受抗PD-(L)-1治疗、伴至少一个无症状非出血性5-20 mm黑色素瘤脑转移且无需立即局部治疗或类固醇的患者。
- 患者接受四剂贝伐珠单抗和帕博利珠单抗每3周一次,随后帕博利珠单抗治疗最长2年。
主要发现
- 脑转移缓解率(主要终点)为54.1%(95%CI 36.9至70.5)。
- 颅外缓解率为56.3%(95%CI 37.7至73.6)。
- 中位颅内无进展生存期为2.2年(95%CI 0.41至未达到[NR])。
- 中位总生存期为4.3年(95%CI 1.6至NR),4年总生存率为51.6%。
- 贝伐珠单抗和帕博利珠单抗的3级治疗相关不良事件率分别为10.8%和18.9%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Anti-vascular endothelial growth factor therapy enhances PD-1 inhibitor activity in preclinical models and has been used to treat perilesional cerebral edema and radiation necrosis. METHODS: We conducted a two-institution phase II trial of bevacizumab and pembrolizumab in patients with untreated melanoma brain metastasis (MBM) (ClinicalTrials.gov identifier: NCT02681549). Patients were anti-PD-(L)-1-naïve, and had ≥one asymptomatic, nonhemorrhagic 5-20 mm MBM, not requiring immediate local therapy or steroids. RESULTS: Thirty-seven patients received four doses of bevacizumab and pembrolizumab every 3 weeks followed by up to 2 years of pembrolizumab. The brain metastasis response rate (primary end point) was 54.1% (95% CI, 36.9 to 70.5). The extracranial response rate was 56.3% (95% CI, 37.7 to 73.6). Median intracranial progression-free survival was 2.2 years (95% CI, 0.41 to not reached [NR]). Median overall survival (OS) was 4.3 years (95% CI, 1.6 to NR). Four-year OS rate was 51.6%. Grade 3 treatment-related adverse event rates from bevacizumab and pembrolizumab were 10.8% and 18.9%, respectively. Higher pretreatment vessel density in metastatic tumors and smaller on-therapy increases in circulating angiopoietin-2 were associated with response. CONCLUSION: Pembrolizumab with bevacizumab was well tolerated and demonstrated substantial activity in patients with untreated MBM with promising OS, justifying further evaluation of this regimen.
引用
- Weiss SA, Djureinovic D, Wei W, et al. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. J Clin Oncol. 2025. PMID: 40048689. doi:10.1200/JCO-24-02219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。